title: Gene therapy and nasopharyngeal carcinoma.
abstract: In 2003, a non-replicating adenoviral gene therapy product received the world`s first government licence for the treatment of head and neck cancer. Two years later approval was granted to a replication-selective adenovirus for the treatment of nasopharyngeal carcinoma in combination with chemotherapy. This review introduces the reader to gene therapy as an emerging treatment modality, and outlines its application to the management of nasopharyngeal carcinoma by examining recent pre-clinical and clinical research.
authors.affiliation: Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary, University of London, London, United Kingdom. jonathanphughes@gmail.com
authors.forename: J
authors.initials: J
authors.lastname: Hughes
authors.forename: G
authors.initials: G
authors.lastname: Alusi
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D002277:Carcinoma; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D006258:Head and Neck Neoplasms / Q000235:genetics / Q000628:therapy; D006801:Humans; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000235:genetics / Q000628:therapy*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
chemical_list: D019941:Cyclin-Dependent Kinase Inhibitor p16; D016159:Tumor Suppressor Protein p53